IDH1 and glioma: Previous work has also considered how molecular markers may be used in clinical decision-making for recurrent surgery for high-grade gliomas particularly for unmethylated MGMT promoter and wildtype IDH1 gliomas—since no other treatment option has demonstrated a survival benefit for these subgroups.